Clinic
Froedtert South, INC.
Froedtert South, INC. was paid $33.07M by Medicaid between Jan 2018 and Dec 2024, across 454 billing codes. Its largest line is 99283, emergency room visit (moderate) — 14% of everything it billed.
33Billing provider infoFROEDTERT SOUTH, INC.
PLEASANT PRAIRIE, WI 53158
PLEASANT PRAIRIE, WI 53158
33aNPI1003831132assigned 07/12/2006
33bProvider typeEnd-Stage Renal Disease (ESRD) Treatment Clinic/Center
28Total paid$33.07M
24GClaims1,501,625
24DCodes billed454
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other End-Stage Renal Disease (ESRD) Treatment Clinic/Center providers in Wisconsin
Rank by total paid#2 of 120
Median peer was paid$662K
This provider vs. median50×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 229,125 | $5.23M | |
| 2019 | 222,555 | $5.00M | |
| 2020 | 184,411 | $4.59M | |
| 2021 | 247,857 | $5.65M | |
| 2022 | 221,578 | $4.73M | |
| 2023 | 222,624 | $4.24M | |
| 2024incomplete | 173,475 | $3.63M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 75,106 | 62,864 | $4.69M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.8% | 43,741 | 37,008 | $2.59M |
| 96361 | Intravenous infusion, hydration; each additional hour | 4.5% | 14,362 | 11,731 | $1.48M |
| 80053 | Comprehensive metabolic panel | 4.4% | 75,774 | 57,470 | $1.47M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.3% | 39,919 | 10,823 | $1.41M |
| 90999 | Dialysis (unlisted procedure)Unlisted dialysis procedure, inpatient or outpatient | 3.6% | 45,640 | 2,878 | $1.17M |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 3.5% | 13,125 | 11,630 | $1.17M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 3.0% | 13,542 | 11,724 | $999K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.8% | 9,757 | 8,387 | $599K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.7% | 8,425 | 5,335 | $566K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.7% | 12,638 | 10,121 | $550K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.6% | 3,219 | 2,964 | $542K |
442 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.6% | 86,928 | $526K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.6% | 13,338 | $513K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.5% | 9,209 | $512K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.3% | 11,965 | $430K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.3% | 7,007 | $429K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.2% | 18,263 | $384K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.1% | 5,372 | $370K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.0% | 16,867 | $342K |
| 99285 | Emergency room visit (most serious) | 1.0% | 6,052 | $340K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.0% | 11,964 | $338K |
| 97113 | <1% | 5,500 | $306K | |
| 80061 | Lipid panel | <1% | 14,382 | $294K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 1,815 | $282K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 6,551 | $277K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 10,411 | $275K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,593 | $270K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 7,694 | $217K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,462 | $200K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 12,095 | $192K |
| G0378 | Hospital observation service, per hour | <1% | 6,675 | $183K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 14,938 | $174K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,656 | $174K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,833 | $166K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 3,652 | $154K |
| 87481 | <1% | 3,324 | $148K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 12,471 | $145K |
| 84484 | <1% | 18,775 | $142K | |
| 81025 | <1% | 19,396 | $142K | |
| 84702 | <1% | 4,921 | $140K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,156 | $137K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 11,467 | $134K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 3,749 | $134K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,369 | $133K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,793 | $126K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 7,202 | $126K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 3,139 | $125K |
| 0240U | <1% | 3,912 | $122K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,720 | $119K |
| 81001 | <1% | 35,705 | $119K | |
| 97162 | <1% | 4,073 | $118K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 3,278 | $117K |
| 82728 | <1% | 6,354 | $117K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 4,338 | $114K |
| 80050 | General health panel | <1% | 5,527 | $107K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,240 | $103K |
| 76830 | Ultrasound, transvaginal | <1% | 3,021 | $101K |
| 82565 | <1% | 8,051 | $99K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 18,822 | $99K |
| 93976 | <1% | 2,677 | $98K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,535 | $96K |
| 87077 | <1% | 5,683 | $94K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,019 | $93K |
| 85027 | <1% | 9,295 | $91K | |
| 87088 | <1% | 14,923 | $89K | |
| 86140 | <1% | 20,079 | $86K | |
| 87653 | <1% | 1,784 | $85K | |
| 87634 | <1% | 1,440 | $85K | |
| 85610 | <1% | 12,765 | $83K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 3,664 | $82K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,383 | $81K |
| 97161 | <1% | 2,126 | $80K | |
| 80081 | <1% | 883 | $77K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,625 | $77K |
| 84439 | <1% | 4,540 | $76K | |
| 82607 | <1% | 4,041 | $75K | |
| 83735 | <1% | 14,260 | $73K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 388 | $72K |
| 82950 | <1% | 2,009 | $72K | |
| 62323 | <1% | 541 | $71K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,173 | $69K |
| 80076 | <1% | 2,672 | $68K | |
| 93017 | <1% | 1,821 | $66K | |
| 83880 | <1% | 3,418 | $64K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,009 | $64K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,723 | $64K |
| 83690 | <1% | 12,306 | $63K | |
| 12001 | <1% | 738 | $62K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 405 | $61K |
| 87480 | <1% | 2,678 | $61K | |
| 93971 | <1% | 2,087 | $59K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,820 | $58K |
| 82947 | <1% | 9,206 | $58K | |
| 59025 | Fetal non-stress test | <1% | 725 | $57K |
| J0606 | Injection, etelcalcetide, 0.1 mg | <1% | 7,598 | $57K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 417 | $55K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,335 | $55K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,154 | $55K |
| 82805 | <1% | 2,523 | $54K | |
| 92557 | <1% | 946 | $52K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 320 | $51K |
| 87506 | <1% | 298 | $48K | |
| 87510 | <1% | 2,678 | $47K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,566 | $46K |
| 80074 | <1% | 905 | $44K | |
| 86481 | <1% | 527 | $43K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 650 | $42K |
| 86592 | <1% | 1,774 | $41K | |
| 87081 | <1% | 2,169 | $39K | |
| 85378 | <1% | 5,856 | $39K | |
| 88142 | <1% | 1,968 | $37K | |
| 94770 | <1% | 1,150 | $37K | |
| 82043 | <1% | 2,883 | $37K | |
| 82105 | <1% | 873 | $37K | |
| 80069 | <1% | 954 | $36K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 13,110 | $36K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,165 | $35K |
| 76801 | <1% | 1,569 | $34K | |
| 87070 | <1% | 1,865 | $33K | |
| 93350 | <1% | 372 | $33K | |
| 83605 | <1% | 4,459 | $31K | |
| 96367 | <1% | 528 | $31K | |
| 87186 | <1% | 4,905 | $31K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 26,811 | $30K |
| 87040 | <1% | 4,141 | $28K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 65 | $28K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 10,279 | $28K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 13,567 | $28K |
| 73630 | <1% | 3,527 | $27K | |
| 82550 | <1% | 3,048 | $26K | |
| 86850 | <1% | 3,736 | $26K | |
| 84145 | <1% | 1,834 | $26K | |
| 83874 | <1% | 1,798 | $24K | |
| 72100 | <1% | 2,213 | $23K | |
| 12011 | <1% | 294 | $23K | |
| 76642 | <1% | 645 | $23K | |
| 85730 | <1% | 6,453 | $23K | |
| 71250 | <1% | 722 | $22K | |
| 88720 | <1% | 424 | $22K | |
| 0002A | <1% | 885 | $22K | |
| 85651 | <1% | 1,770 | $22K | |
| 97802 | <1% | 1,441 | $22K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 588 | $21K |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 70 | $21K |
| 86803 | <1% | 1,855 | $20K | |
| 70486 | <1% | 662 | $20K | |
| 83540 | <1% | 3,695 | $20K | |
| 93970 | <1% | 564 | $20K | |
| 0001A | <1% | 900 | $20K | |
| 86762 | <1% | 1,241 | $20K | |
| 92567 | <1% | 1,201 | $19K | |
| 76536 | <1% | 469 | $19K | |
| 64493 | <1% | 113 | $19K | |
| 74150 | <1% | 344 | $19K | |
| 83550 | <1% | 3,402 | $18K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 236 | $18K |
| 82746 | <1% | 1,603 | $18K | |
| 81002 | <1% | 4,770 | $17K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 465 | $17K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 231 | $17K |
| 10060 | <1% | 211 | $17K | |
| 84153 | <1% | 1,042 | $17K | |
| 84550 | <1% | 3,091 | $16K | |
| 87660 | <1% | 1,179 | $16K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 459 | $15K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 20,838 | $15K |
| 12002 | <1% | 182 | $15K | |
| 70498 | <1% | 217 | $15K | |
| 87340 | <1% | 2,451 | $15K | |
| 70496 | <1% | 197 | $15K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 408 | $14K |
| 73030 | <1% | 2,374 | $14K | |
| 82784 | <1% | 678 | $14K | |
| 87210 | <1% | 2,343 | $14K | |
| 72141 | <1% | 244 | $13K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,971 | $13K |
| 85652 | <1% | 5,097 | $13K | |
| 91300 | <1% | 2,109 | $13K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 681 | $13K |
| 97166 | <1% | 635 | $12K | |
| 82553 | <1% | 1,774 | $12K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 647 | $12K |
| 84100 | <1% | 4,491 | $12K | |
| 74018 | <1% | 1,382 | $11K | |
| 82948 | <1% | 2,605 | $11K | |
| 86901 | <1% | 4,989 | $11K | |
| 82247 | <1% | 398 | $11K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 37,612 | $11K |
| 86900 | <1% | 4,415 | $11K | |
| 86480 | <1% | 215 | $11K | |
| 83516 | <1% | 925 | $10K | |
| 97803 | <1% | 500 | $10K | |
| 73562 | <1% | 3,103 | $10K | |
| 76770 | <1% | 224 | $10K | |
| 64494 | <1% | 67 | $10K | |
| 86038 | <1% | 977 | $10K | |
| 97116 | <1% | 881 | $9K | |
| 92595 | <1% | 179 | $9K | |
| 73610 | <1% | 2,851 | $8K | |
| 0003A | <1% | 262 | $8K | |
| 83970 | <1% | 1,087 | $8K | |
| C8923 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, without spectral or color doppler echocardiography | <1% | 107 | $8K |
| 73130 | <1% | 2,280 | $8K | |
| 81003 | <1% | 3,165 | $8K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 6,481 | $8K |
| 87493 | <1% | 247 | $7K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,044 | $7K |
| 36592 | <1% | 2,110 | $7K | |
| 83615 | <1% | 1,431 | $7K | |
| 64635 | <1% | 52 | $7K | |
| 0031A | <1% | 254 | $7K | |
| 64636 | <1% | 50 | $7K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 17 | $7K |
| 84132 | <1% | 1,047 | $7K | |
| 87522 | Neg quan hep c or qual rna | <1% | 194 | $6K |
| 82150 | <1% | 460 | $6K | |
| 29125 | <1% | 143 | $6K | |
| 93356 | <1% | 83 | $6K | |
| 73502 | <1% | 1,297 | $6K | |
| 43249 | <1% | 39 | $6K | |
| 95806 | <1% | 98 | $6K | |
| 82010 | <1% | 899 | $6K | |
| 87420 | <1% | 345 | $5K | |
| 86039 | <1% | 590 | $5K | |
| 87205 | <1% | 1,840 | $5K | |
| 86430 | <1% | 1,135 | $5K | |
| 90715 | <1% | 969 | $5K | |
| 71045 | Radiologic examination, chest; single view | <1% | 8,744 | $5K |
| 81511 | <1% | 55 | $5K | |
| 96415 | <1% | 66 | $5K | |
| 82677 | <1% | 204 | $5K | |
| 87075 | <1% | 685 | $5K | |
| G0109 | Diabetes outpatient self-management training services, group session (2 or more), per 30 minutes | <1% | 206 | $5K |
| J0882 | Injection, darbepoetin alfa, 1 microgram (for esrd on dialysis) | <1% | 6,526 | $5K |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 363 | $4K |
| 99001 | <1% | 412 | $4K | |
| 80177 | <1% | 259 | $4K | |
| 93321 | <1% | 57 | $4K | |
| 84403 | <1% | 197 | $4K | |
| 82951 | <1% | 86 | $4K | |
| 90686 | <1% | 390 | $4K | |
| 71271 | <1% | 58 | $4K | |
| 73110 | <1% | 1,578 | $3K | |
| 86336 | <1% | 204 | $3K | |
| 77080 | <1% | 54 | $3K | |
| 82248 | <1% | 715 | $3K | |
| 84703 | <1% | 229 | $3K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 62 | $3K |
| 74183 | <1% | 32 | $3K | |
| 43235 | <1% | 13 | $3K | |
| 86780 | <1% | 282 | $3K | |
| 93308 | <1% | 25 | $3K | |
| 70491 | <1% | 40 | $3K | |
| 93923 | <1% | 60 | $3K | |
| 85018 | <1% | 4,399 | $3K | |
| 92591 | <1% | 14 | $3K | |
| 84112 | <1% | 42 | $2K | |
| 86706 | <1% | 112 | $2K | |
| C8928 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report | <1% | 25 | $2K |
| G0008 | Administration of influenza virus vaccine | <1% | 387 | $2K |
| 72072 | <1% | 167 | $2K | |
| 93880 | <1% | 62 | $2K | |
| 73564 | <1% | 120 | $2K | |
| 88304 | <1% | 1,118 | $2K | |
| 73221 | <1% | 39 | $2K | |
| 73080 | <1% | 780 | $2K | |
| 29515 | <1% | 29 | $2K | |
| 88342 | <1% | 2,692 | $2K | |
| 91303 | <1% | 253 | $2K | |
| 92552 | <1% | 17 | $2K | |
| 83001 | <1% | 93 | $2K | |
| 84520 | <1% | 5,164 | $2K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 28 | $2K |
| 0124A | <1% | 74 | $2K | |
| 97597 | <1% | 23 | $2K | |
| 84480 | <1% | 99 | $2K | |
| 80164 | <1% | 89 | $1K | |
| 86618 | <1% | 52 | $1K | |
| 86160 | <1% | 83 | $1K | |
| 87324 | <1% | 102 | $1K | |
| 76942 | <1% | 129 | $1K | |
| 76870 | <1% | 26 | $1K | |
| 80175 | <1% | 25 | $1K | |
| 86665 | <1% | 33 | $1K | |
| 97165 | <1% | 44 | $1K | |
| 64488 | <1% | 45 | $1K | |
| 82274 | <1% | 12 | $1K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 81 | $1K |
| 82952 | <1% | 100 | $1K | |
| 83655 | <1% | 43 | $1K | |
| 29130 | <1% | 14 | $1K | |
| 94010 | <1% | 53 | $1K | |
| 86317 | <1% | 222 | $1K | |
| 94642 | <1% | 28 | $1K | |
| 73140 | <1% | 887 | $1K | |
| 86308 | <1% | 70 | $1K | |
| 72050 | <1% | 127 | $1K | |
| 82533 | <1% | 16 | $1K | |
| 74230 | <1% | 13 | $989.36 | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 516 | $967.22 |
| 76000 | <1% | 94 | $934.85 | |
| 84460 | <1% | 594 | $920.23 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 16,788 | $907.05 |
| 87449 | <1% | 124 | $895.63 | |
| 92555 | <1% | 21 | $861.67 | |
| 93225 | <1% | 25 | $848.70 | |
| 82310 | <1% | 577 | $805.19 | |
| 72110 | <1% | 27 | $799.37 | |
| 87899 | <1% | 62 | $797.28 | |
| 95886 | <1% | 12 | $796.63 | |
| 71101 | <1% | 488 | $756.59 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,256 | $752.57 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 3,081 | $747.39 |
| 74022 | <1% | 711 | $732.87 | |
| 82140 | <1% | 47 | $716.14 | |
| 73590 | <1% | 408 | $699.65 | |
| 76999 | <1% | 29 | $681.60 | |
| 84155 | <1% | 608 | $656.98 | |
| 82378 | <1% | 31 | $639.80 | |
| 94060 | <1% | 26 | $630.85 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 163 | $629.15 |
| 82570 | <1% | 147 | $575.03 | |
| 86664 | <1% | 33 | $573.99 | |
| 96376 | <1% | 2,048 | $564.36 | |
| 86580 | <1% | 14 | $563.16 | |
| 94727 | <1% | 259 | $552.66 | |
| 87046 | <1% | 93 | $544.53 | |
| 0072A | <1% | 44 | $522.65 | |
| 86200 | <1% | 58 | $513.74 | |
| L3908 | Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf | <1% | 349 | $504.42 |
| 93325 | <1% | 41 | $496.87 | |
| 86663 | <1% | 33 | $492.46 | |
| 87015 | <1% | 50 | $489.22 | |
| 86235 | <1% | 14 | $481.78 | |
| 97163 | <1% | 14 | $465.43 | |
| 84165 | <1% | 59 | $425.76 | |
| 93296 | <1% | 40 | $408.42 | |
| 86735 | <1% | 48 | $379.46 | |
| 86765 | <1% | 48 | $374.67 | |
| 73090 | <1% | 95 | $343.22 | |
| 87147 | <1% | 82 | $317.53 | |
| 94729 | <1% | 276 | $312.81 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 3,464 | $304.85 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,957 | $297.54 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 12,504 | $294.54 |
| 86225 | <1% | 27 | $291.48 | |
| 83883 | <1% | 13 | $283.26 | |
| 90656 | <1% | 34 | $267.73 | |
| L1830 | Knee orthosis, immobilizer, canvas longitudinal, prefabricated, off-the-shelf | <1% | 296 | $252.17 |
| 86334 | <1% | 13 | $248.45 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 5,462 | $225.52 |
| 84156 | <1% | 89 | $221.91 | |
| 88307 | <1% | 104 | $219.12 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,496 | $170.83 |
| 86812 | <1% | 17 | $163.91 | |
| J2704 | Injection, propofol, 10 mg | <1% | 8,493 | $158.05 |
| 77065 | Tomosynthesis, mammo | <1% | 12 | $154.76 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,969 | $145.17 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,419 | $142.84 |
| 76376 | <1% | 55 | $135.00 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 10,144 | $133.73 |
| 72170 | <1% | 64 | $122.06 | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 299 | $120.44 |
| 73560 | <1% | 50 | $104.83 | |
| V2632 | Posterior chamber intraocular lens | <1% | 437 | $101.77 |
| J1097 | Phenylephrine 10.16 mg/ml and ketorolac 2.88 mg/ml ophthalmic irrigation solution, 1 ml | <1% | 24 | $101.45 |
| 94760 | <1% | 1,512 | $93.23 | |
| 76998 | <1% | 119 | $91.69 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,411 | $86.81 |
| 77066 | Tomosynthesis, mammo | <1% | 12 | $86.66 |
| 84466 | <1% | 244 | $77.70 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 128 | $75.57 |
| 82040 | <1% | 400 | $75.17 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 913 | $70.21 |
| 51798 | <1% | 120 | $62.86 | |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | <1% | 57 | $62.36 |
| 86923 | <1% | 45 | $54.62 | |
| 84295 | <1% | 410 | $52.90 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 2,120 | $49.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 1,198 | $48.63 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,398 | $46.39 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 7,906 | $43.43 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 6,103 | $42.25 |
| 82374 | <1% | 393 | $41.22 | |
| J2501 | Injection, paricalcitol, 1 mcg | <1% | 23,475 | $37.68 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,726 | $20.82 |
| C1769 | Guide wire | <1% | 205 | $16.77 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,086 | $15.74 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 98 | $12.57 |
| L1906 | Ankle foot orthosis, multiligamentous ankle support, prefabricated, off-the-shelf | <1% | 389 | $12.56 |
| V5266 | Battery for use in hearing device | <1% | 16 | $12.35 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 797 | $11.61 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,919 | $9.11 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 1,818 | $7.00 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 567 | $6.59 |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | <1% | 1,280 | $6.25 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 2,299 | $6.25 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,564 | $5.86 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 568 | $5.01 |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 19 | $2.77 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 632 | $2.05 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 705 | $1.49 |
| J2372 | Injection, phenylephrine hydrochloride (biorphen), 20 micrograms | <1% | 45 | $0.89 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 82 | $0.50 |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | <1% | 17 | $0.11 |
| 91312 | <1% | 68 | $0.09 | |
| 91305 | <1% | 25 | $0.02 | |
| 91307 | <1% | 51 | $0.01 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 98 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 2,241 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 264 | $0.00 |
| J1250 | Injection, dobutamine hydrochloride, per 250 mg | 0% | 25 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 148 | $0.00 |
| 99406 | 0% | 67 | $0.00 | |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 46 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 59 | $0.00 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 43 | $0.00 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 34 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 892 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 63 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 242 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 77 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 17 | $0.00 |
| G8991 | Other physical or occupational therapy primary functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 33 | $0.00 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | 0% | 46 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 33 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 17 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 92 | $0.00 |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | 0% | 26 | $0.00 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 25 | $0.00 |
| J0604 | Cinacalcet, oral, 1 mg, (for esrd on dialysis) | 0% | 14 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 15 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 16 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 339 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 1,696 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 152 | $0.00 |
| S0028 | Injection, famotidine, 20 mg | 0% | 59 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 280 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 272 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 295 | $0.00 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 30 | $0.00 |
| J0736 | Injection, clindamycin phosphate, 300 mg | 0% | 13 | $0.00 |
| C1776 | Joint device (implantable) | 0% | 25 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 177 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 57 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 110 | $0.00 |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | 0% | 101 | $0.00 |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | 0% | 15 | $0.00 |
| J0694 | Injection, cefoxitin sodium, 1 gm | 0% | 17 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 16 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 96 | $0.00 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 19 | $0.00 |
| 51701 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKELLEY, THOMAS (VP & CFO)
| Provider | Location | Paid |
|---|---|---|
| Froedtert South, INC. | Kenosha, WI | $5.22M |
| Town of Marshfield | Marshfield, MA | $329K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.